Through you again, Mr. Chair, we followed the testimony closely. There are four things that cover our conduct in Canada.
First is the Food and Drugs Act, the law of the land. As we've noted, we support the improvements proposed before this committee in Bill C-17. Second is our code of ethical practices. When it comes to the distribution of information and promotion, we are also guided by the parameters of the Pharmaceutical Advertising Advisory Board, or PAAB, and Advertising Standards Canada.
There is a great degree of rigour in the context of what our members can do. Again, by law and by our code, we can promote only the approved indication and label.